Cart (0 Items)
Your cart is currently empty.
View ProductsSize | 100ug |
---|---|
Brand | Arovia |
Product type | Recombinant Proteins |
Product name | Recombinant Monkey IL37/IL1F7 Protein, N-His |
---|---|
Origin species | Macaca fascicularis (Crab-eating macaque) (Cynomolgus monkey) |
Expression system | Prokaryotic expression |
Molecular weight | 27.76 kDa |
Buffer | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
Form | Liquid |
Delivery condition | Dry Ice |
Delivery lead time in business days | 3-5 days if in stock; 3-5 weeks if production needed |
Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
Brand | Arovia |
Host species | Escherichia coli (E.coli) |
Fragment Type | Met1-Asp235 |
Aliases /Synonyms | FIL1Z, IL37, Interleukin-1-related protein, IL-23, IL1F7, IL-37, IL1RP1, FIL1 zeta, IL-1X, Interleukin-23, IL-1F7, IL-1RP1, Interleukin-1 family member 7, Interleukin-37, Interleukin-1 homolog 4, Interleukin-1 zeta, IL-1H, IL-1H4, IL-1 zeta, IL1H4, |
Reference | ARO-P10917 |
Note | For research use only. |
Recombinant Monkey IL37/IL1F7 protein is a highly promising therapeutic protein that has gained significant attention in recent years due to its potential in treating various inflammatory and autoimmune disorders. This protein is a member of the interleukin-1 family and is encoded by the IL37 gene in monkeys. It has been found to exhibit potent anti-inflammatory properties, making it a potential candidate for the development of novel therapies. In this article, we will provide a comprehensive description of the structure, activity, and applications of recombinant Monkey IL37/IL1F7 protein.
Recombinant Monkey IL37/IL1F7 protein is a 37-kDa protein that belongs to the IL-1 family of cytokines. It is composed of 218 amino acids and shares significant sequence homology with human IL37. The protein contains a signal peptide at its N-terminus, which is responsible for its secretion. The mature form of the protein consists of four alpha-helices and a beta-sheet, which is characteristic of the IL-1 family. It also contains a conserved cysteine-rich domain, which is essential for its biological activity.
Recombinant Monkey IL37/IL1F7 protein has been found to have potent anti-inflammatory properties, making it a promising therapeutic candidate for various inflammatory and autoimmune disorders. It exerts its anti-inflammatory effects by binding to the IL-18 receptor alpha chain and inhibiting the activation of the NF-κB signaling pathway. This results in the downregulation of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Moreover, recombinant Monkey IL37/IL1F7 protein has been shown to promote the differentiation of regulatory T cells, which play a crucial role in maintaining immune homeostasis.
Recombinant Monkey IL37/IL1F7 protein has shown promising results in preclinical studies and has the potential to be used in the treatment of various inflammatory and autoimmune disorders. Some of the potential applications of this protein include:
RA is a chronic inflammatory disorder that affects the joints and can lead to severe disability. Recombinant Monkey IL37/IL1F7 protein has been found to inhibit the production of pro-inflammatory cytokines and reduce the severity of joint inflammation in animal models of RA. It has also been shown to reduce the production of antibodies against collagen, which is a hallmark of RA.
IBD is a group of chronic inflammatory disorders of the gastrointestinal tract, including Crohn’s disease and ulcerative colitis. Recombinant Monkey IL37/IL1F7 protein has been found to reduce the severity of colitis in animal models by inhibiting the production of pro-inflammatory cytokines and promoting the differentiation of regulatory T cells.
Psoriasis is a chronic inflammatory skin disorder that is characterized by red, scaly patches on the skin. Recombinant Monkey IL37/IL1F7 protein has been shown to reduce the severity of psoriasis in animal models by inhibiting the production of pro-inflammatory cytokines and promoting the differentiation of regulatory T cells.
SLE is a chronic autoimmune disorder that can affect multiple organs in the body. Recombinant Monkey IL37/IL1F7 protein has been found to reduce the severity of lupus nephritis, a common complication of SLE, by inhibiting the production of pro-inflammatory cytokines and promoting the differentiation of regulatory T cells.
Recom
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.